论文部分内容阅读
有人提出把肾素血管紧张素系统(renin-angio-tensin system,RAS)阻断剂放入饮用水中以防止肾病的发生发展,降低心血管风险,并可通过评估尿微量白蛋白的消长来判定这些风险。这一观念已受到挑战,其原因是由于评估尿微量白蛋白(一种心脏病、肾病危险性标志物)改变的前瞻性临床试验数据与流行病学研究结果不一致。
It has been proposed to place a renin-angio-tensin system (RAS) blocker in drinking water to prevent the development of nephropathy and reduce cardiovascular risk and to evaluate the effects of urinary albumin Determine these risks. This concept has been challenged because of inconsistent data from epidemiological studies in assessing urinary albumin (a cardiac, risk marker of nephropathy) changes in prospective clinical trials.